Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cenvacibart for prevention of stroke and systemic embolism in adults with atrial fibrillation unsuitable for oral anticoagulation
NL-OMON61670Phase 3Not yet recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Atrial fibrillation (AFib) and atrial flutter (AFL) comparing Cenvacibart with Placebo (2 arms). Primary endpoints: Time to first occurrence of ischemic stroke or systemic embolism and Time to first occurrence of ISTH major bleeding. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
cenvacibart
03
Conditions
Atrial fibrillation (AFib)atrial flutter (AFL)
Beyond the preview
Go deeper on NL-OMON61670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61670.